LEXINGTON, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent
Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office
has decided not to grant the Company's Post Grant Review (PGR) petition
challenging the validity of U.S. Patent No. 9,662,335 (referred to as
the '335 patent) assigned to Incyte Pharmaceuticals.
"We are disappointed that the PTAB has denied our petition on the '335
patent. This decision does not prohibit us from challenging the validity
of the patent at a later time in federal court, and we will continue
with our plans to develop CTP-543 for alopecia areata. We don't expect
any disruption to our clinical timelines," said Roger Tung, President
and CEO of Concert Pharmaceuticals. "We remain committed to developing
the first FDA-approved treatment for alopecia areata; however, we are
reassessing whether to expand CTP-543 into additional indications."
In July 2017, Concert filed a PGR petition challenging the validity of
Incyte's '335 patent covering deuterated ruxolitinib analogs. Documents
relating to the PGR can be accessed online at: http://www.concertpharma.com/technology-overview/intellectual-property/.
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to address unmet patient needs. The Company's
approach starts with approved drugs in which deuterium substitution has
the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad
pipeline of innovative medicines targeting autoimmune and
inflammatory diseases and central nervous systems (CNS) disorders. For
more information please visit www.concertpharma.com
or follow us on Twitter at @ConcertPharma
or on LinkedIn.
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about the strength of
Concert's intellectual property, and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict," "project,"
"should," "target," "would," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including factors discussed in the
"Risk Factors" section of our most recent Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission and in other filings
that we make with the Securities and Exchange Commission. In addition,
any forward-looking statements included in this press release represent
our views only as of the date of this release and should not be relied
upon as representing our views as of any subsequent date. We
specifically disclaim any obligation to update any forward-looking
statements included in this press release.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180112005093/en/
Concert Pharmaceuticals, Inc.
Kathryn Morris, 914-204-6412
Source: Concert Pharmaceuticals, Inc.
News Provided by Acquire Media